Targeting the tumour microenvironment in ovarian cancer

European Journal of Cancer

Volumn 56, Issue , 2016, Pages 131-143

  Hansen, Jean M ^a   Coleman, Robert L ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ovarian cancer; Tumour microenvironment

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; PLATINUM DERIVATIVE; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT;

BONE MARROW CELL; CANCER CELL; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CYTOREDUCTIVE SURGERY; DRUG TARGETING; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; MACROPHAGE; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION (PATHOLOGY); OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84957564275     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.12.016     Document Type: Review

References (151)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70
2. K. Pietras, and A. Ostman Hallmarks of cancer: interactions with the tumor stroma Exp Cell Res 316 8 2010 1324 1331
3. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 1 2015 5 29
4. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal Global cancer statistics, 2012 CA Cancer J Clin 2015
5. R.J. Morgan Jr., R.D. Alvarez, D.K. Armstrong, B. Boston, R.A. Burger, L. Chen, and et al. Epithelial ovarian cancer J Natl Compr Canc Netw 9 1 2011 82 113
6. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 11 2010 803 808
7. D.W. Kindelberger, Y. Lee, A. Miron, M.S. Hirsch, C. Feltmate, F. Medeiros, and et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2 2007 161 169
8. K. Levanon, C. Crum, and R. Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 32 2008 5284 5293
9. A. Flesken-Nikitin, C. Hwang, C. Cheng, T.V. Michurina, G. Enikolopov, and A.Y. Nikitin Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche Nature 495 7440 2013 241 245
10. S. Pradeep, S.W. Kim, S.Y. Wu, M. Nishimura, P. Chaluvally-Raghavan, T. Miyake, and et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread Cancer Cell 26 1 2014 77 91
11. K.G. Phillips, C. Ruiz Velasco, J. Li, A. Kolatkar, M. Luttgen, K. Bethel, and et al. Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient Front Oncol 2 2012 72
12. K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, and et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 17 11 2011 1498 1503
13. J.J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R.A. Brown Myofibroblasts and mechano-regulation of connective tissue remodelling Nat Rev Mol Cell Biol 3 5 2002 349 363
14. H.Y. Chang, J.T. Chi, S. Dudoit, C. Bondre, M. van de Rijn, D. Botstein, and et al. Diversity, topographic differentiation, and positional memory in human fibroblasts Proc Natl Acad Sci U S A 99 20 2002 12877 12882
15. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 5 2006 392 401
16. G. Gabbiani, G.B. Ryan, and G. Majne Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction Experientia 27 5 1971 549 550
17. M.H. Sieweke, N.L. Thompson, M.B. Sporn, and M.J. Bissell Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta Science 248 4963 1990 1656 1660
18. J. Cai, H. Tang, L. Xu, X. Wang, C. Yang, S. Ruan, and et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness Carcinogenesis 33 1 2012 20 29
19. A. Desmouliere, M. Redard, I. Darby, and G. Gabbiani Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar Am J Pathol 146 1 1995 56 66
20. K. Rasanen, and A. Vaheri Activation of fibroblasts in cancer stroma Exp Cell Res 316 17 2010 2713 2722
21. D.S. Dolberg, R. Hollingsworth, M. Hertle, and M.J. Bissell Wounding and its role in RSV-mediated tumor formation Science 230 4726 1985 676 678
22. H.F. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 26 1986 1650 1659
23. P. Cirri, and P. Chiarugi Cancer associated fibroblasts: the dark side of the coin Am J Cancer Res 1 4 2011 482 497
24. R.J. McAnulty Fibroblasts and myofibroblasts: their source, function and role in disease Int J Biochem Cell Biol 39 4 2007 666 671
25. D. Fukumura, R. Xavier, T. Sugiura, Y. Chen, E. Park, N. Lu, and et al. Tumor induction of VEGF promoter activity in stromal cells Cell 94 6 1998 715 725
26. D. Granot, Y. Addadi, V. Kalchenko, A. Harmelin, L.A. Kunz-Schughart, and M. Neeman In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors Cancer Res 67 19 2007 9180 9189
27. E.S. Jeon, H.J. Moon, M.J. Lee, H.Y. Song, Y.M. Kim, M. Cho, and et al. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells Stem Cells 26 3 2008 789 797
28. E. Heller, M.A. Hurchla, J. Xiang, X. Su, S. Chen, J. Schneider, and et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment Cancer Res 72 4 2012 897 907
29. L.G. Harris, R.S. Samant, and L.A. Shevde Hedgehog signaling: networking to nurture a promalignant tumor microenvironment Mol Cancer Res 9 9 2011 1165 1174
30. C. Dierks, J. Grbic, K. Zirlik, R. Beigi, N.P. Englund, G. Guo, and et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies Nat Med 13 8 2007 944 951
31. Y. Zhang, H. Tang, J. Cai, T. Zhang, J. Guo, D. Feng, and et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion Cancer Lett 303 1 2011 47 55
32. I.G. Schauer, A.K. Sood, S. Mok, and J. Liu Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer Neoplasia 13 5 2011 393 405
33. A. Gilead, G. Meir, and M. Neeman The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids Int J Cancer 108 4 2004 524 531
34. P. Mhawech-Fauceglia, L. Yan, M. Sharifian, X. Ren, S. Liu, G. Kim, and et al. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer Cancer Microenviron 2014
35. H. Itamochi, N. Oumi, T. Oishi, F. Taniguchi, T. Shoji, H. Fujiwara, and et al. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach Int J Gynecol Cancer 25 4 2015 570 576
36. Q. Yao, X. Qu, Q. Yang, M. Wei, and B. Kong CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer Oncol Rep 22 3 2009 541 548
37. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
38. H. Kiaris, I. Chatzistamou, G. Trimis, M. Frangou-Plemmenou, A. Pafiti-Kondi, and A. Kalofoutis Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis Cancer Res 65 5 2005 1627 1630
39. N. Wernert, C. Locherbach, A. Wellmann, P. Behrens, and A. Hugel Presence of genetic alterations in microdissected stroma of human colon and breast cancers Anticancer Res 21 4A 2001 2259 2264
40. N.M. Hawsawi, H. Ghebeh, S. Hendrayani, A. Tulbah, M. Al-Eid, T. Al-Tweigeri, and et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes Cancer Res 68 8 2008 2717 2725
41. J.A. Ledermann, A. Hackshaw, S. Kaye, G. Jayson, H. Gabra, I. McNeish, and et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 29 28 2011 3798 3804
42. A. Du Bois, G. Kristensen, I. Ray-Coquard, A. Reuss, S. Pignata, N. Colombo, and et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy+/-nintedanib for advanced ovarian cancer Int J Gynecol Cancer 23.8 Suppl. 1 2013
43. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 8 2008 592 603
44. H.J. Choi, G.N. Armaiz Pena, S. Pradeep, M.S. Cho, R.L. Coleman, and A.K. Sood Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches Cancer Metastasis Rev 34 1 2015 19 40
45. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 3 1996 353 364
46. J. Folkman Anti-angiogenesis: new concept for therapy of solid tumors Ann Surg 175 3 1972 409 416
47. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1971 1182 1186
48. S. Brem, H. Brem, J. Folkman, D. Finkelstein, and A. Patz Prolonged tumor dormancy by prevention of neovascularization in the vitreous Cancer Res 36 8 1976 2807 2812
49. L. Holmgren, M.S. O'Reilly, and J. Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 2 1995 149 153
50. R.S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis 21 3 2000 505 515
51. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, and et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 5422 1999 1994 1998
52. R. Folberg, M.J. Hendrix, and A.J. Maniotis Vasculogenic mimicry and tumor angiogenesis Am J Pathol 156 2 2000 361 381
53. A.J. Maniotis, R. Folberg, A. Hess, E.A. Seftor, L.M.G. Gardner, J. Pe'er, and et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry Am J Pathol 155 3 1999 739 752
54. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 6801 2000 249 257
55. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 6423 1993 841 844
56. N. Ferrara VEGF as a therapeutic target in cancer Oncology 69 Suppl. 3 2005 11 16
57. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 7070 2005 967 974
58. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 19 2008 2039 2049
59. G.L. Semenza Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 10 2003 721 732
60. T. Tammela, G. Zarkada, E. Wallgard, A. Murtomaki, S. Suchting, M. Wirzenius, and et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation Nature 454 7204 2008 656 660
61. H.P. Gerber, A.K. Malik, G.P. Solar, D. Sherman, X.H. Liang, G. Meng, and et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism Nature 417 6892 2002 954 958
62. W.A. Spannuth, A.M. Nick, N.B. Jennings, G.N. Armaiz Pena, L.S. Mangala, C.G. Danes, and et al. Functional significance of VEGFR-2 on ovarian cancer cells Int J Cancer 124 5 2009 1045 1053
63. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 9698 2009 1371 1382
64. M.R. Stockler, F. Hilpert, M. Friedlander, M.T. King, L. Wenzel, C.K. Lee, and et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer J Clin Oncol 32 13 2014 1309 1316
65. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, G. Kristensen, and et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J Clin Oncol 32 13 2014 1302 1308
66. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
67. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, and et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
68. R.K. Jain Molecular regulation of vessel maturation Nat Med 9 6 2003 685 693
69. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 9 2003 1287 1295
70. R. Erber, A. Thurnher, A.D. Katsen, G. Groth, H. Kerger, H.P. Hammes, and et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2 2004 338 340
71. N. Jo, C. Mailhos, M. Ju, E. Cheung, J. Bradley, K. Nishijima, and et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization Am J Pathol 168 6 2006 2036 2053
72. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, C. Zarwan, and et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 33 2009 5601 5606
73. F.A. Raja, C.L. Griffin, W. Qian, H. Hirte, M.K. Parmar, A.M. Swart, and et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer Br J Cancer 105 7 2011 884 889
74. J.A. Ledermann, T.J. Perren, and F.A. Raja Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. ESMO 2013 Abstract No. 10
75. J.F. Liu, W.T. Barry, M. Birrer, J.M. Lee, R.J. Buckanovich, G.F. Fleming, and et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study Lancet Oncol 15 11 2014 1207 1214
76. D. Matei, M.W. Sill, H.A. Lankes, K. DeGeest, R.E. Bristow, D. Mutch, and et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial J Clin Oncol 29 1 2011 69 75
77. T.J. Herzog, G. Scambia, B.G. Kim, C. Lhomme, J. Markowska, I. Ray-Coquard, and et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma Gynecol Oncol 130 1 2013 25 30
78. M. Friedlander, K.C. Hancock, D. Rischin, M.J. Messing, C.A. Stringer, G.M. Matthys, and et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol Oncol 119 1 2010 32 37
79. A. du Bois, A. Floquet, J.W. Kim, J. Rau, J.M. del Campo, M. Friedlander, and et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer J Clin Oncol 32 30 2014 3374 3382
80. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, M. Russell, and et al. VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 17 2002 11393 11398
81. R.L. Coleman, L.R. Duska, P.T. Ramirez, J.V. Heymach, A.A. Kamat, S.C. Modesitt, and et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Lancet Oncol 12 12 2011 1109 1117
82. W.H. Gotlieb, F. Amant, S. Advani, C. Goswarni, H. Hirte, D. Provencher, and et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 13 2 2012 154 162
83. J.L. Li, and A.L. Harris Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications Front Biosci (Landmark Ed) 14 2009 3094 3110
84. J.L. Li, R.C.A. Sainson, C.E. Oon, H. Turley, R. Leek, H. Sheldon, and et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo Cancer Res 71 18 2011 6073 6083
85. J. Condeelis, and J.W. Pollard Macrophages: obligate partners for tumor cell migration, invasion, and metastasis Cell 124 2 2006 263 266
86. C. Scavelli, B. Nico, T. Cirulli, R. Ria, G. Di Pietro, D. Mangieri, and et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma Oncogene 27 5 2008 663 674
87. R.P. Negus, G.W. Stamp, J. Hadley, and F.R. Balkwill Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines Am J Pathol 150 5 1997 1723 1734
88. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 6917 2002 860 867
89. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 9255 2001 539 545
90. D.M. Parkin The global health burden of infection-associated cancers in the year 2002 Int J Cancer 118 2002 3030 3044
91. A. Ekbom, C. Helmick, M. Zack, and H.O. Adami Ulcerative colitis and colorectal cancer. a population-based study N Engl J Med 323 18 1990 1228 1233
92. S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.Y. Yu, S. Vallabhapurapu, and et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Cancer Cell 15 2 2009 103 113
93. F. Balkwill, K.A. Charles, and A. Mantovani Smoldering and polarized inflammation in the initiation and promotion of malignant disease Cancer Cell 7 3 2005 211 217
94. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 3 2012 309 322
95. S.A. Rosenberg IL-2: the first effective immunotherapy for human cancer J Immunol 192 12 2014 5451 5458
96. S.A. Rosenberg, P. Spiess, and R. Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 4770 1986 1318 1321
97. R.O. Dillman, N.M. Barth, R.K. Oldham, R.J. Cohen, D.R. Minor, R. Birch, and et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. a national biotherapy study group trial Cancer 68 1 1991 1 8
98. S.A. Rosenberg, and M.E. Dudley Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 2 2009 233 240
99. L.E. Kandalaft, D.J. Powell, N. Singh, and G. Coukos Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29 7 2011 925 933
100. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, and et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 3 2003 203 213
101. A.C. Halpern, and L.M. Schuchter Prognostic models in melanoma Semin Oncol 24 1 Suppl. 4 1997 S2 7
102. Y. Naito, K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, H. Nagura, and et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Res 58 16 1998 3491 3494
103. A.J. Marrogi, A. Munshi, A.J. Merogi, Y. Ohadike, A. El-Habashi, O.L. Marrogi, and et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma Int J Cancer 74 5 1997 492 501
104. S. Vesalainen, P. Lipponen, M. Talja, and K. Syrjanen Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma Eur J Cancer 30A 12 1994 1797 1803
105. O. Nakano, M. Sato, Y. Naito, K. Suzuki, S. Orikasa, M. Aizawa, and et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity Cancer Res 61 13 2001 5132 5136
106. K. Schumacher, W. Haensch, C. Roefzaad, and P.M. Schlag Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas Cancer Res 61 10 2001 3932 3936
107. S.F. Adams, D.A. Levine, M.G. Cadungog, R. Hammond, A. Facciabene, N. Olvera, and et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer Cancer 115 13 2009 2891 2902
108. A.M. Vlad, R.A. Budiu, D.E. Lenzer, Y. Wang, J.A. Thaller, K. Colonello, and et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer Cancer Immunol Immunother 59 2 2010 293 301
109. K. Fujita, H. Ikarashi, K. Takakuwa, S. Kodama, A. Tokunga, T. Takahashi, and et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes Clin Cancer Res 1 5 1995 501 507
110. F.S. Hodi, M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, M.V. Seiden, and et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 8 2003 4712 4717
111. F.S. Hodi, M. Butler, D.A. Oble, M.V. Seiden, G.F. Haluska, A. Kruse, and et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 8 2008 3005 3010
112. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 12 1999 1365 1369
113. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, and et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 7 2000 1027 1034
114. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2 2012 207 212
115. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 8 2002 793 800
116. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
117. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
118. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, and et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 9 2007 3360 3365
119. K. Abiko, M. Mandai, J. Hamanishi, Y. Yoshioka, N. Matsumura, T. Baba, and et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction Clin Cancer Res 19 6 2013 1363 1374
120. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, and et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer J Clin Oncol. 32 5 Suppl 2014
121. M.L. Disis Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial J Clin Oncol 33 2015 suppl; abstr 5509
122. A. Varga Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study J Clin Oncol 33 2015 suppl; abstr 5510
123. W. Peng, R. Jiang, X. Wu, Z. Li, M. Sun, B. Yu, and et al. PDL1, PDL2, and CD8+ TIL expression in ovarian carcinosarcoma J Clin Oncol 33 15 Suppl. 2015
124. P. Allavena, A. Sica, G. Solinas, C. Porta, and A. Mantovani The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages Crit Rev Oncol Hematol 66 1 2008 1 9
125. A. Mantovani, B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco The origin and function of tumor-associated macrophages Immunol Today 13 7 1992 265 270
126. A. Mantovani, P. Allavena, S. Sozzani, A. Vecchi, M. Locati, and A. Sica Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors Semin Cancer Biol 14 3 2004 155 160
127. J.W. Pollard Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 1 2004 71 78
128. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol 23 11 2002 549 555
129. A. Mantovani, A. Sica, and M. Locati Macrophage polarization comes of age Immunity 23 4 2005 344 346
130. T. Schioppa, B. Uranchimeg, A. Saccani, S.K. Biswas, A. Doni, A. Rapisarda, and et al. Regulation of the chemokine receptor CXCR4 by hypoxia J Exp Med 198 9 2003 1391 1402
131. S.S. Dave, G. Wright, B. Tan, A. Rosenwald, R.D. Gascoyne, W.C. Chan, and et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 351 21 2004 2159 2169
132. C. Cursiefen, L. Chen, L.P. Borges, D. Jackson, J. Cao, C. Radziejewski, and et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J Clin Invest 113 7 2004 1040 1050
133. S. Huang, M. Van Arsdall, S. Tedjarati, M. McCarty, W. Wu, R. Langley, and et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice J Natl Cancer Inst 94 15 2002 1134 1142
134. M. Egeblad, and Z. Werb New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 3 2002 161 174
135. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy Eur J Cancer 42 6 2006 717 727
136. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 5 2004 623 633
137. J. Youn, S. Nagaraj, M. Collazo, and D.I. Gabrilovich Subsets of myeloid-derived suppressor cells in tumor-bearing mice J Immunol 181 8 2008 5791 5802
138. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 3 2009 162 174
139. N. Mirza, M. Fishman, I. Fricke, M. Dunn, A.M. Neuger, T.J. Frost, and et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Res 66 18 2006 9299 9307
140. S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination Cancer Res 63 15 2003 4441 4449
141. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 7378 2011 480 489
142. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, and et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 9 2004 942 949
143. L. Yang, L.M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, Y. Shyr, and et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis Cancer Cell 6 4 2004 409 421
144. C. Murdoch, M. Muthana, S.B. Coffelt, and C.E. Lewis The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 8 2008 618 631
145. R. Kim, M. Emi, K. Tanabe, and K. Arihiro Tumor-driven evolution of immunosuppressive networks during malignant progression Cancer Res 66 11 2006 5527 5536
146. J.E. Ohm, and D.P. Carbone VEGF as a mediator of tumor-associated immunodeficiency Immunol Res 23 2-3 2001 263 272
147. S. Ju, D.J. Panka, H. Cui, R. Ettinger, M. El-Khatib, D.H. Sherr, and et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation Nature 373 6513 1995 444 448
148. A. Strasser, P.J. Jost, and S. Nagata The many roles of FAS receptor signaling in the immune system Immunity 30 2 2009 180 192
149. G.T. Motz, S.P. Santoro, L. Wang, T. Garrabrant, R.R. Lastra, I.S. Hagemann, and et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Nat Med 20 6 2014 607 615
150. J.S. Yu, P.K. Lee, M. Ehtesam, K. Samoto, K.L. Black, and C.J. Wheeler Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium J Neurooncol 64 1-2 2003 55 61
151. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, A. Husain, and et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 2012 2039 2045